1. Home
  2. JRVR vs NKTX Comparison

JRVR vs NKTX Comparison

Compare JRVR & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JRVR
  • NKTX
  • Stock Information
  • Founded
  • JRVR 2002
  • NKTX 2015
  • Country
  • JRVR Bermuda
  • NKTX United States
  • Employees
  • JRVR N/A
  • NKTX N/A
  • Industry
  • JRVR Property-Casualty Insurers
  • NKTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • JRVR Finance
  • NKTX Health Care
  • Exchange
  • JRVR Nasdaq
  • NKTX Nasdaq
  • Market Cap
  • JRVR 181.2M
  • NKTX 170.8M
  • IPO Year
  • JRVR 2005
  • NKTX 2020
  • Fundamental
  • Price
  • JRVR $4.28
  • NKTX $1.84
  • Analyst Decision
  • JRVR Buy
  • NKTX Strong Buy
  • Analyst Count
  • JRVR 4
  • NKTX 6
  • Target Price
  • JRVR $6.06
  • NKTX $15.00
  • AVG Volume (30 Days)
  • JRVR 538.7K
  • NKTX 2.4M
  • Earning Date
  • JRVR 03-03-2025
  • NKTX 03-26-2025
  • Dividend Yield
  • JRVR 0.96%
  • NKTX N/A
  • EPS Growth
  • JRVR N/A
  • NKTX N/A
  • EPS
  • JRVR N/A
  • NKTX N/A
  • Revenue
  • JRVR $707,626,000.00
  • NKTX N/A
  • Revenue This Year
  • JRVR $13.51
  • NKTX N/A
  • Revenue Next Year
  • JRVR $5.87
  • NKTX N/A
  • P/E Ratio
  • JRVR N/A
  • NKTX N/A
  • Revenue Growth
  • JRVR N/A
  • NKTX N/A
  • 52 Week Low
  • JRVR $3.00
  • NKTX $1.31
  • 52 Week High
  • JRVR $9.56
  • NKTX $11.84
  • Technical
  • Relative Strength Index (RSI)
  • JRVR 50.28
  • NKTX 52.57
  • Support Level
  • JRVR $4.13
  • NKTX $1.31
  • Resistance Level
  • JRVR $4.38
  • NKTX $2.34
  • Average True Range (ATR)
  • JRVR 0.16
  • NKTX 0.16
  • MACD
  • JRVR 0.06
  • NKTX 0.06
  • Stochastic Oscillator
  • JRVR 77.36
  • NKTX 51.46

About JRVR James River Group Holdings Ltd.

James River Group Holdings Ltd owns and operates a group of specialty insurance and reinsurance companies. It reports business into three segments. The Excess and Surplus Lines segment, which is the key revenue driver, offers commercial excess and surplus lines liability and excess property insurance products; The Specialty Admitted Insurance segment focuses on niche classes within the standard insurance markets with a primary focus on fronting business, where it retains a minority share of the risk and seek to earn fee income by allowing other carriers and producers to use its licensure, ratings, expertise and infrastructure. and the Corporate and other segment consists of the management and treasury activities of holding companies, equity compensation for the group.

About NKTX Nkarta Inc.

Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.

Share on Social Networks: